Menu
X

Tags Archives: Medical Innovation


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
3 weeks ago CAR-T

Why Does China Have a Unique Advantage in the Field of CAR-T Therapy?

**Why Does China Have a Unique Advantage in the Field of CAR-T Therapy?**

CAR-T

CAR-T

#CAR_Therapy #CancerTreatment #MedicalInnovation #ChinaMedical

In recent years, China has made rapid advancements in medical technology, particularly in the area of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This cutting-edge cancer treatment involves reprogramming a patient’s own T cells to recognize and attack cancer cells. This revolutionary therapy has transformed treatment options for various malignancies, with China’s innovations and applications standing out globally.

### 1. **Scientific Innovation and Technological Breakthroughs**

China has reached a world-leading level in CAR-T research and development. Numerous prestigious medical schools and research institutions in China have actively contributed to this field, leading to the creation of several novel CAR-T treatment methods. Chinese scientists have pioneered significant innovations in CAR-T cell engineering, toxicity control, and target selection. For example, the CD19 CAR-T therapy for hematologic malignancies is widely used in China. Additionally, the fully human BCMA-targeted CAR-T product, Equecabtagene Autoleucel, used for multiple myeloma, has achieved a complete remission (CR) rate of 82.4%. Recently, *Nature* featured China’s breakthrough in using universal CAR-T for autoimmune diseases. New CAR-T therapies targeting solid tumors are also progressing rapidly.

### 2. **Cost-Effectiveness and Extensive Clinical Application**

Compared to some Western countries, CAR-T therapy in China is more affordable, partially due to lower production and R&D costs. A surge of local pharmaceutical and biotech companies has emerged, promoting the domestic production of CAR-T products and reducing reliance on imported drugs. This efficient supply chain management has not only lowered treatment costs but also made the personalized therapy more accessible to patients. While CAR-T therapy in the U.S. can cost $700,000–$800,000, the cost in China is about one-fifth to one-seventh of that.

Moreover, the faster approval process for clinical trials in China enables researchers to quickly bring new therapies to market, allowing patients earlier access to innovative treatments. This efficiency is supported by streamlined regulatory frameworks and healthcare reforms.

### 3. **Government Policy Support and International Collaboration**

The Chinese government has implemented various policies to strongly support biomedical innovation, including the development and application of CAR-T technology. For example, the National Medical Products Administration (NMPA) has accelerated the approval process for CAR-T therapies, simplifying regulatory procedures, and encouraging international cooperation and technology transfer. Many international pharmaceutical giants have partnered with Chinese companies to jointly advance CAR-T therapy research and commercialization. This openness has established China as a key global center for CAR-T treatment.

### 4. **Large Patient Population Driving Research and Application**

As the most populous country, China has a vast cancer patient population, providing abundant clinical cases and research resources for the application and further optimization of CAR-T therapy. This large patient base allows China to conduct large-scale clinical trials in a short time, accelerating the validation of treatment effectiveness and maturity. In China, not only are there local consensus guidelines for CAR-T usage, but each physician applying CAR-T has significant experience in both initial treatments and post-therapy management.

### 5. **Interdisciplinary Collaboration and Development**

China’s advancements in cellular immunotherapy are not solely dependent on progress in medical fields but are also supported by the integration of interdisciplinary technologies such as artificial intelligence, gene editing, and materials science. For instance, AI is increasingly playing a role in optimizing and personalizing CAR-T therapy designs. Gene editing tools like CRISPR are also widely applied in China for designing CAR-T cells, making them more precise and effective.

### Conclusion

China’s unique advantages in CAR-T therapy stem from continuous scientific breakthroughs, lower treatment costs, strong government support, and a vast patient base. As technology advances and international collaborations deepen, China is poised to play an increasingly important role in the global fight against cancer. CAR-T therapy offers new hope to cancer patients, and China’s innovation and strength are helping bring this hope to fruition sooner.

This is not just China’s advantage; it is a blessing for cancer patients worldwide.

🎉🎉To assess whether the condition is suitable for clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#ChimericAntigenReceptor #CancerResearch #Immunotherapy #ChinaMedicalAdvancements #Biotech #GeneTherapy #CellTherapy #HealthcareRevolution #CancerCare #AIinHealthcare #PrecisionMedicine #GlobalHealth


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
2 months ago Solid tumor

Published in Cell Journal | Breakthrough in dMMR Metastatic Colorectal Cancer Treatment: Chinese Research Garners International Recognition

**Published in Cell Journal | Breakthrough in dMMR Metastatic Colorectal Cancer Treatment: Chinese Research Garners International Recognition**

Colorectal Cancer

Colorectal Cancer

#ColorectalCancer #PD1Antibody #dMMR #cell #cellpress #Med #PD-1 #CellJournal

A Chinese medical team has made a significant breakthrough in the treatment of dMMR (deficient mismatch repair) metastatic colorectal cancer. Recently, their latest research findings were published in the *Med* journal, a subsidiary of *Cell*, offering new treatment hope for patients with advanced colorectal cancer.

The study revealed that the combination of PD-1 antibody immunotherapy with COX inhibitors, drugs commonly used for anti-inflammatory treatment, significantly improved treatment effectiveness. This innovative strategy could substantially increase survival chances for patients with advanced colorectal cancer.

Colorectal cancer is the second most common cancer in China, and its incidence is on the rise. While PD-1 antibody immunotherapy has brought hope to some patients, its success rate is only 45%. Approximately 30% of dMMR metastatic colorectal cancer patients are resistant to PD-1 treatment. Therefore, the Chinese team explored combining PD-1 immunotherapy with COX inhibitors (such as celecoxib and aspirin) to overcome this resistance.

The team’s Phase 2 clinical trial yielded remarkable results. Among the 30 patients who received the combination therapy, the overall response rate was 73.3%, a 30% improvement over PD-1 monotherapy. After more than four years of follow-up, 65% of patients achieved progression-free survival, and 90% were still alive. Four patients reached complete remission, while 11 others underwent surgery, with 10 showing complete pathological remission.

In addition to the notable clinical outcomes, genomic and immunological analysis revealed that high expression of the TAPBP protein was associated with better treatment results. This discovery opens new avenues for the development of biomarkers to predict treatment response and for personalized treatment plans in the future.

Following the publication of the study, it attracted significant attention from the international medical community. Experts from Memorial Sloan Kettering Cancer Center in the U.S. wrote a commentary in the *Med* journal, highly praising the innovative therapy. They noted that the combination of COX inhibitors with PD-1 treatment not only increased the complete remission rate but also reduced immune suppression signals in the tumor microenvironment, enhancing the effectiveness of PD-1 therapy, with manageable side effects.

This research offers new hope for dMMR metastatic colorectal cancer patients worldwide, and further large-scale clinical trials are expected to confirm its efficacy. The combination of COX inhibitors with PD-1 immunotherapy could become a safe and effective treatment option for dMMR metastatic colorectal cancer patients, providing hope for long-term survival.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!
WhatsApp: +8613717959070

(Https://wa.me/+8613717959070)
Email: doctor.huang@globecancer.com

#CancerResearch #MedicalInnovation #GlobalHealth #Immunotherapy #Colorectal #COXInhibitors


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
2 months ago Hematological Neoplasms , CAR-T

**Breakthrough in China’s CAR-T Therapy: 13-Year-Old Girl Overcomes Lupus, Opening New Hope for a Cure**

**Breakthrough in China’s CAR-T Therapy: 13-Year-Old Girl Overcomes Lupus, Opening New Hope for a Cure**

Lupus

Lupus

#LupusTreatment #HopeForLupus #lupus #AutoimmuneDisease #ChinaHealthcare #SystemicLupusErythematosus #Erythematosus #patientstory #SLE

    In June 2024, 13-year-old Qingqing experienced a major turning point in her life. A year after being diagnosed with systemic lupus erythematosus (SLE), she received innovative CAR-T therapy at Shanghai Children’s Medical Center and successfully achieved disease remission. SLE, often referred to as the “incurable cancer,” is an autoimmune disease that affects millions of people worldwide, severely damaging the brain, lungs, kidneys, and blood system. Even when not in an acute flare, patients often suffer from chronic symptoms such as fatigue, rashes, pain, and fever.

    Qingqing’s treatment marks a significant breakthrough in the global fight against SLE. Previously, SLE patients could only rely on lifelong medications, such as steroids and immunosuppressants, to control the disease and prevent severe complications. However, these drugs often come with side effects and long-term organ damage. Qingqing’s case has offered the world new hope. A team led by Dr. Li Benshang, chief physician of the Hematology and Oncology Department, and Dr. Yin Lei, head of the Nephrology Department, pioneered the use of CAR-T therapy in SLE treatment and initiated a clinical study. After just two months of treatment, Qingqing’s condition has fully gone into remission, and all medications were discontinued.

    CAR-T therapy was originally used in cancer treatment by extracting a patient’s T cells and genetically modifying them to recognize and kill abnormal cells in the body. In the treatment of SLE, CAR-T therapy eliminates the abnormal plasma cells producing autoantibodies, effectively “resetting” the patient’s immune system and addressing the root cause of the disease.

    Qingqing’s success story is not only a milestone in China’s CAR-T technology but also a major leap forward in the global treatment of autoimmune diseases like SLE. Since the first CAR-T treatment cured an SLE patient in 2021, numerous clinical trials have been conducted worldwide, and several Chinese hospitals have also achieved success. However, while early results are encouraging, further research and validation are needed to confirm the long-term safety and efficacy of the treatment.

    With 20% of the global population affected by various types of autoimmune diseases, CAR-T therapy holds the potential to bring new life to millions of patients. China’s ongoing research and international collaboration in this field offer unprecedented hope for overcoming persistent diseases like SLE.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

 (Https://wa.me/+8613717959070)

Email: doctor.huang@globecancer.com

#CAR-Ttherapy #LupusTreatment #AutoimmuneDisease #MedicalInnovation #ChinaHealthcare #Immunotherapy #CancerTreatment #HealthBreakthrough #HopeForLupus #FutureOfMedicine


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
2 months ago Solid tumor

**Breaking News!  China’s Cancer Drug Outperforms Global PD-1 Inhibitor!**

**Breaking News!  China’s Cancer Drug Outperforms Global PD-1 Inhibitor!**

PD1

PD1

#AK112 #CancerDrug #PD-1 #PD1Inhibitor #CancerTreatment #BispecificAntibody #NSCLC

China’s pharmaceutical industry has reached a historic milestone! Remember AK112 (Ivonescimab), which took center stage during this year’s ASCO conference, attracting global attention for its groundbreaking potential? The long wait is finally over, and the results are in!

In May, Akeso Biopharma, a leading Chinese pharmaceutical company, announced that its independently developed bispecific antibody drug AK112 achieved a major milestone in clinical trials. AK112 demonstrated superior efficacy to the globally renowned PD-1 inhibitor Keytruda (K Drug) in treating PD-L1-positive non-small cell lung cancer (NSCLC), marking a revolutionary breakthrough for China’s innovative cancer treatments.

**Clinical Data that Surprised the World**

During the World Conference on Lung Cancer 2024, Professor Zhou Caicun, one of China’s top lung cancer experts, revealed the results of the HARMONi-2 study, which had the entire audience applauding. The data exceeded expectations, demonstrating that AK112 is not just on par with but superior to international “superstar” cancer drugs in several key areas.

– **Progression-Free Survival (PFS):** AK112 improved PFS by an astonishing 91.4% compared to Keytruda, reaching 11.14 months versus 5.82 months.

– **Risk Reduction:** AK112 reduced the risk of disease progression or death by 49%.

– **Objective Response Rate (ORR):** AK112 outperformed Keytruda with a response rate of 50.0% compared to 38.5%.

– **Disease Control Rate (DCR):** AK112 maintained a significant advantage, achieving 89.9% versus 70.5%.

While AK112 showed slightly higher Grade 3 side effects due to its VEGF inhibition, its overall performance remains remarkable. Although overall survival (OS) data is still maturing, AK112’s impressive PFS results suggest that its survival benefits will likely be just as extraordinary.

**The Power of Bispecific Antibodies**

AK112 is part of a new class of cancer drugs called bispecific antibodies, capable of targeting two different antigens at once. In this case, AK112 targets both PD-1 and VEGF, two well-known lung cancer markers. This dual-target approach offers patients better therapeutic options and increased convenience, potentially replacing the traditional combination of PD-1 inhibitors with anti-angiogenic drugs like Avastin.

This breakthrough has made AK112 the first and only bispecific antibody drug to outperform Keytruda in head-to-head clinical trials, solidifying its place as a future game-changer in cancer treatment.

**A Milestone for China’s Pharma Industry**

In May 2024, AK112 received regulatory approval from China’s National Medical Products Administration (NMPA) for treating EGFR-mutated, locally advanced, or metastatic NSCLC, becoming the world’s first approved PD-1/VEGF bispecific antibody.

This marks a monumental achievement for China’s pharmaceutical innovation. AK112’s success demonstrates that Chinese researchers and drug developers, in just two decades, have achieved what took developed nations over a century. China’s presence at top-tier global cancer conferences like ASCO and ESMO has never been stronger, with clinical data that leaves the world in awe.

China’s pharmaceutical industry may have started late, but its rapid progress is a testament to the ingenuity and hard work of its researchers. Once relying on generics, China is now a leader in pharmaceutical innovation, offering cutting-edge treatments to patients around the globe. The future of cancer treatment is here, and it’s painted in the bold color of “China Red.”

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China  for preliminary evaluation!

WhatsApp: +8613717959070

Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #MedicalInnovation #PharmaBreakthrough #ChinaPharma #AK112 #LungCancer #BispecificAntibody #PD1Inhibitor #GlobalHealth #MedicalAdvancements #ProudlyMadeInChina #WorldClass


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
5 months ago Solid tumor

Nature Medicine | New Hope! Chinese Medical Team Makes Breakthrough in Gastric Adenocarcinoma Treatment

Nature Medicine | **New Hope! Chinese Medical Team Makes Breakthrough in Gastric Adenocarcinoma Treatment**

Nature Medicine

Nature Medicine

In the medical field, unresectable advanced or metastatic gastric or gastroesophageal junction (#GEJ) adenocarcinoma has always been a daunting challenge. However, the latest research brings new hope to this field. #metastaticgastric #gastroesophagealjunction

**Innovative Treatment Brings New Hope**

The latest study published in *Nature Medicine* indicates that the drug Cadonilimab, in combination with chemotherapy, has significant efficacy and safety for patients with HER2-negative unresectable advanced or metastatic gastric or GEJ adenocarcinoma. This study, jointly conducted by scholars such as Jiafu Ji, Ziyu Li, and Lin Shen from Peking University, brings exciting news to this field.

**Key Findings**

Key findings of the study include:
– Cadonilimab in combination with chemotherapy has significant benefits for tumor response and survival, offering patients a ray of hope.
– The median overall survival reached 17.48 months in all patients, with higher benefits observed in patients with higher PD-L1 expression, reaching a median overall survival of 20.32 months in patients with PD-L1 CPS≥5.
– Even in patients with PD-L1 CPS<1, encouraging survival benefits were observed, with a median overall survival of 17.64 months.
– The drug demonstrated good safety profile, with treatment-related adverse events being manageable and tolerable.

**Dawning of Hope**

This study brings new hope to patients with gastric adenocarcinoma or GEJ adenocarcinoma. Regardless of PD-L1 expression, Cadonilimab in combination with chemotherapy exhibits encouraging clinical activity and manageable safety. This innovative treatment regimen holds the promise of fundamentally changing this life-threatening disease worldwide.

**Conclusion**

This groundbreaking research highlights the leading position of Chinese medical teams in the field of gastric adenocarcinoma treatment. With further research, we hope to see more innovative treatment options emerge, providing patients with more opportunities for survival and better quality of life. Let us look forward to the progress of medical science and bring more hope for health!
Want to know more Advanced medicine in China, You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address: doctor.huang@globecancer.com
or WhatsApp 137 1795 9070.
The Medical Department will contact you as soon as they receive the reports.


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
6 months ago CAR-T

Historic Moment! Chinese Medical Team Successfully Cures Diabetes Patient

🌟✨ **Historic Moment! Chinese Medical Team Successfully Cures Diabetes Patient** ✨🌟

Diabetes

Diabetes

In an exhilarating milestone moment, China’s medical technology has reached new heights! In a groundbreaking technological breakthrough, a Chinese medical team has successfully cured the world’s first case of type 2 diabetes through autologous regenerated pancreatic islet transplantation, marking a tremendous success in diabetes treatment! The patient has now been completely free from insulin for 33 months. 🎉🎊
On May 7th, a reporter from The Paper News learned from the Second Affiliated Hospital of Naval Medical University (Shanghai Changzheng Hospital) that on April 30th, Professor Yin Hao’s team from the hospital, in collaboration with Professor Cheng Xin’s team from the Chinese Academy of Sciences Molecular Cell Science Excellence Innovation Center, published their research findings online in the international academic journal “Cell Discovery” under the title “Treating a type 2 diabetic patient with impaired pancreatic islet function by personalized endoderm stem cell-derived islet tissue.” This is the first reported case internationally of successful treatment of severely impaired pancreatic islet function in diabetes using autologous stem cell-derived pancreatic islet transplantation.

🩸 **Miracle of Health Restoration**

This deeply touching story originates from a 59-year-old male who has suffered from diabetes for 25 years. After years of suffering, his diabetes had progressed to end-stage, facing numerous threats of complications. However, through the relentless efforts of Chinese scientists and doctors, he finally found the path to regaining his health.

🔬 **Technological Redemption**

Chinese scientists utilized cutting-edge stem cell technology to reprogram the patient’s own cells into endoderm stem cells, ultimately cultivating “seed cells” in vitro and reconstructing pancreatic islet tissue. This technology not only completely transformed the life of this patient but also brought new hope to diabetes patients worldwide.

🌱 **A New Era of Regenerative Medicine**

This is not just a technological breakthrough but also a revolutionary challenge to the medical community. The success of the Chinese medical team has opened a new door for diabetes patients worldwide, bringing endless possibilities.

👩‍⚕️ **Future Prospects**

And this is just the beginning! Chinese scientists and doctors will continue to strive for further research, aiming to develop more advanced regenerative medical technologies and provide more effective treatment solutions for diabetes patients worldwide.

🌍 **The World Changes Because of China**

This feat not only signifies the rise of Chinese medicine but also serves as a model for China’s technological development. With its unique technological prowess and medical innovation, China is increasingly demonstrating its influence on the world stage.
Want more info about #pancreaticislet
doctor.huang@globecancer.com
WhatsApp: 137 1795 9070


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
7 months ago CAR-T

China’s First CAR-T Trial: “Pay-for-Performance” Introduced!

China’s First CAR-T Trial: “Pay-for-Performance” Introduced! 💉💰

CAR-T

CAR-T

🎉 China has taken a groundbreaking step towards pay-for-performance! Fosun Kite announces an exciting initiative: the ¥1.2 million(RMB) #CARTcell therapy will now be paid based on its effectiveness! 💊💸

 

NO CR – Refund

🌟 This means that eligible patients using Fosun Kite’s #CARTtherapy, #Axicabtagene Ciloleucel, will undergo effectiveness assessment three months after drug purchase and infusion. If complete remission (CR) is not achieved, patients will receive a refund of up to ¥600,000(RMB)! 💰✨

👨‍⚕️ This innovative payment model

is not only China’s first for lymphoma drugs but also the country’s first for bio-innovative drugs! 💉🚀

is an immunotherapy method that involves genetically modifying a patient’s T cells outside the body to recognize specific tumor targets before reinfusing them to precisely combat #tumors. Currently, five products, including Fosun Kite’s #AxicabtageneCiloleucel, have been approved domestically. 💪🔍

     As a form of immunotherapy, CAR-T cell therapy works by collecting a patient’s T cells and genetically modifying them outside the body to recognize specific tumor targets. These modified T cells are then reintroduced into the patient, enabling precise targeting and attacking of tumors. Currently, there are five approved products domestically, including Axicabtagene Ciloleucel from Fosun Kite, Relmacabtagene Autoleucel from JW Therapeutics, Equecabtagene Autoleucel from IASO Bio, Inaticabtagene Autoleucel from Juventas, and Zevorcabtagene autoleucel from CARsgen.

 

New Hope

💡 Unlike traditional drugs, CAR-T requires individualized production for each patient, thus incurring higher costs. However, this innovative pay-for-performance model brings new hope to patients! 🌈💊

“Cure” standards

📏 Fosun Kite’s project leader stated that they will collaborate with clinical experts, health commissions, treatment demonstration centers, and other stakeholders to establish “Cure” standards, objectively assessing lymphoma efficacy. This will provide reliable evaluation criteria for performance-based payment! 👩‍⚕️📈

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
7 months ago CAR-T

Approval of #Liver Cancer CAR-T Product Targeting #GPC3 Propels China’s CAR-T Therapy Forward

🎯Approval of #Liver Cancer CAR-T Product Targeting #GPC3 Propels China’s CAR-T Therapy Forward🎯

Liver cancer, CAR-T

Liver cancer, CAR-T

CT011

🎀On January 15, 2024, #CARsgen Pharmaceuticals announced that its autologous #CARTcell candidate product #CT011, targeting Glypican-3 (GPC3), has been approved for clinical use in China. It is intended for the treatment of GPC3-positive stage IIIa hepatocellular carcinoma patients at risk of recurrence after surgical resection.

Glypican-3 (GPC3)

    🌺Glypican-3 (GPC3)plays a crucial role in regulating cell growth and differentiation and is closely associated with the occurrence and progression of liver cancer. GPC3 is expressed in reproductive system tumors such as hepatocellular carcinoma, ovarian clear cell carcinoma, and yolk sac tumors. Its expression rate in hepatocellular carcinoma reaches 74.8%, while it is virtually absent in normal liver tissue, making it an ideal new target for #livercancer #CARTtherapy.

 

Promising Target

🌸Due to its tumor specificity, GPC3 is considered a promising target for cancer immunotherapy. Higher expression of GPC3 in hepatocellular carcinoma is associated with poorer prognosis.

 

Frontiers in Immunology

🐚In August 2022, a Chinese medical team published a long-term survival case report of treating advanced hepatocellular carcinoma with CT011 in the journal “#FrontiersinImmunology.” The study reported complete remission (#CR) and long-term survival in a patient with advanced hepatocellular carcinoma after receiving GPC3 CAR-T cell therapy in combination with the multi-target kinase inhibitor sorafenib.

🌼Results showed good tolerance to CT011 combined with sorafenib treatment. The patient achieved partial remission (PR) from the third month onwards and attained complete remission at the 12th month after the first CT011 infusion. The tumor did not progress for over 36 months, maintaining complete remission status for over 24 months after the first infusion.

 

Cancer Communications

🌷On October 12, 2023, CARsgen Pharmaceuticals announced the clinical efficacy of its independently developed CAR-T cell therapy targeting GPC3 in two patients with advanced hepatocellular carcinoma (HCC). The clinical trial results were published in “#CancerCommunications.” Both patients had inferior prognostic outcomes upon enrollment, with one having inferior vena cava tumor thrombus and the other having retroperitoneal lymph node metastasis.

🍄In the clinical trial, one patient received local treatment for intrahepatic recurrent tumors and inferior vena cava tumor thrombus (microwave ablation and gamma knife) before receiving CAR-T cell therapy targeting GPC3. Six months later, AFP (alpha-fetoprotein) levels normalized, and imaging revealed no active tumors. The other patient underwent local treatment (microwave ablation and gamma knife) for controlling intrahepatic tumors, inferior vena cava tumor thrombus, and peritoneal lymph node metastases while receiving CAR-T cell therapy.

🎈Encouragingly, both patients showed significant efficacy after combined local treatment and CAR-T cell infusion, maintaining tumor-free status during long-term follow-up, with both individuals being tumor-free for over 7 years. Throughout the follow-up period, both patients only received oral antiviral therapy for hepatitis B and did not undergo any other cancer treatment.

🎉🎉To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

📞WhatsApp: +8613717959070

💌Email: doctor.huang@globecancer.com


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
8 months ago Myeloma

Cross-Border Medical Innovation: Singaporean Patient Confronts Multiple Myeloma in China – A Decisive Journey with CAR-T Therapy

Cross-Border Medical Innovation: Singaporean Patient Confronts Multiple Myeloma in China – A Decisive Journey with CAR-T Therapy

Multiple Myeloma

Multiple Myeloma

    Singaporean patient, Teresa has been battling multiple myeloma for nearly three years. Despite undergoing various conventional treatments including multi-drug therapy, radiation, and chemotherapy, her condition relapsed with extramedullary plasmacytomas affecting her brain, liver, and multiple bones. Recently, after an online consultation with Dr. Vicky Lee and her team at Shanghai Jiahui International Hospital, she made a significant decision: to undergo FUCASO CAR-T therapy in China.

    China not only possesses global-leading clinical experience in CAR-T therapy but also offers high-quality commercialized CAR-T products at a competitive price in the global market. Currently, there is an ample supply of these CAR-T products available in China, which is crucial for patients racing against time. Furthermore, the convenience of a single infusion has attracted international attention.

    At Shanghai Jiahui International Hospital, an experienced team of hematologic oncology specialists will tailor a personalized treatment plan for Teresa, providing comprehensive and refined diagnostic and therapeutic services. As a pioneer in CAR-T therapy, Jiahui Hospital is about to bring new hope to Ms. Teresa.

    We will continue to monitor Teresa’s treatment progress and provide updates.

#CART #CARTTherapy #HopeReborn #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
8 months ago CAR-T

ความหวังใหม่สำหรับผู้ป่วยโรคมีเลือดมาก (Multiple Myeloma) – เริ่มต้นการรักษาด้วย CAR-T Therapy

🎯ความหวังใหม่สำหรับผู้ป่วยโรคมีเลือดมาก (Multiple Myeloma) – เริ่มต้นการรักษาด้วย CAR-T Therapy🎯

⭐เมื่อเร็ว ๆ นี้ ทีมของศาสตราจารย์ ดร. ลิ ปิง ณ โรงพยาบาลตงจิ ในเซี่ยงไฮ้ ได้ดำเนินการรักษาด้วยการภูมิคุ้มกันเซลล์ T ที่มีภูมิลักษณ์ผสม (Chimeric Antigen Receptor T-Cell Immunotherapy หรือ CAR-T) สำเร็จสำหรับผู้ป่วยโรคมีเลือดมากที่ซ้ำกลับและซ้ำแล้วและซ้ำไม่ได้ (R/RMM) นี่เป็นการรักษาที่เปิดโอกาสใหม่สำหรับการรักษาผู้ป่วย R/RMM

🌟ผู้ป่วยที่ได้รับการรักษาด้วย CAR-T นี้ได้รับการวินิจฉัยว่าเป็นโรคมีเลือดมากในเดือนกรกฎาคม พ.ศ. 2564 ในประเทศไทย โรคมีเลือดมากของผู้ป่วยมีภาระรักษามาก โรครุนแรง แม้จะได้รับการรักษาด้วยเคมีบำบัดระบบทั่วไป โมโนคลอนอนิบอดี้ การปลูกถ่ายเซลล์ลำไส้โภชนาการของตนเอง (ASCT) และการรักษาอื่น ๆ โรคยังกลับมาซ้ำกลับหลายครั้ง ในระยะเวลาของโรคเพียง 2 ปี เข้าสู่การรักษาหลายเส้นทาง และเจริญสามารถรับการรักษาอย่างเป็นตัวอย่าง ไม่สามารถควบคุมโรคได้อย่างมีประสิทธิภาพ

🌠 เมื่อจำนวนการเกิดการซ้ำกลับเพิ่มขึ้นในผู้ป่วย R/RMM และจำนวนของเส้นทางการรักษาขยายออก การตอบสนองต่อการรักษาก็เลวร้ายลงและระยะเวลาของการหายตัวยังกลับมาสั้นลง อย่างไรก็ตาม ด้วยการอนุมัติยา CAR-T therapy ที่เป็นมนุษย์ที่สมบูรณ์แบบแรกในโลก ชื่อ FUCASO (Eque-cel) ในจีนใหญ่ ความหวังใหม่ก็ได้ถูกเปิดขึ้นอย่างไม่สงบสำหรับการรักษาโรคมีเลือดมาก โครงสร้าง CAR ที่เป็นมนุษย์ที่สมบูรณ์แบบของมันไม่เพียงแต่มีความต้านทานต่อร่างกายน้อย แต่ยังมีการปลดตัวออกและการใช้งานต่ำ ทำให้ผู้ป่วยสามารถกลับไปสู่ระดับคุณภาพชีวิตที่สูงขึ้นด้วยการรักษาแค่ครั้งเดียว

☄หลังจากทีมของศาสตราจารย์ ดร. ลิ ปิง ประเมินพิจารณาพบว่าผู้ป่วยมีเงื่อนไขที่เหมาะสมสำหรับการรักษาด้วยเซลล์ CAR-T หลังจากการสื่อสารอย่างเต็มที่ระหว่างแพทย์กับผู้ป่วยและครอบครัวของเขา ผู้ป่วยในที่สุดก็เลือกที่จะรับการรักษาด้วย CAR-T และได้ทำการรวบรวมเซลล์โมโนเนวกลุ่มเลือดเป็นรายในเดือนพฤศจิกายน พ.ศ. 2566

✨ เราจะติดตามความคืบหน้าของการรักษาของผู้ป่วยต่อไปและรายงานติดตามต่อไป

#CARTTreatment #CARTTherapy #HopeReborn #FUCASOApproval #EquecelApproval #MultipleMyeloma #TongjiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

หมายเหตุ: ภาพถ่ายและข้อมูลได้รับอนุญาตจากโรงพยาบาล ผู้ป่วย และครอบครัวของผู้ป่วย


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
8 months ago Myeloma , CAR-T

Hope Reborn for Multiple Myeloma Patients – The Beginning of CAR-T Therapy

🎯Hope Reborn for Multiple Myeloma Patients – The Beginning of CAR-T Therapy🎯

⭐ Recently, Professor Li Ping’s team at Tongji Hospital in Shanghai successfully carried out Chimeric Antigen Receptor T-Cell Immunotherapy (CAR-T) treatment for a relapsed and refractory multiple myeloma (R/RMM) patient. This therapy brings new hope for the treatment of R/RMM patients.
🌟 The patient who underwent CAR-T treatment was diagnosed with multiple myeloma in Thailand in July 2021. With a high tumor burden and aggressive disease, despite receiving systemic chemotherapy, monoclonal antibodies, autologous hematopoietic stem cell transplantation (ASCT), and other treatments, the disease recurred multiple times. Within just 2 years of the disease course, the patient developed resistance to multi-line treatments, making it difficult to control the disease effectively.

🌠 As the number of relapses increases in R/RMM patients and the number of treatment lines expands, the response to treatment worsens, and the duration of remission becomes shorter. However, with the approval of the world’s first fully human CAR-T therapy drug, FUCASO (Eque-cel), in mainland China, new hope has undoubtedly been ignited for the treatment of multiple myeloma. Its breakthrough fully human CAR structure not only has low immunogenicity but also rapid dissociation and low exhaustion, allowing patients to return to a higher quality of life with just one treatment.

☄ After evaluation by Professor Li Ping’s team, the patient met the criteria for CAR-T cell therapy. After thorough communication between doctors and the patient and their family, the patient ultimately chose to undergo CAR-T therapy and completed peripheral blood mononuclear cell collection in November 2023.

✨ We will continue to monitor the patient’s treatment progress and provide follow-up reports.

#CARTTreatment #CARTTherapy #HopeReborn #FUCASOApproval #EquecelApproval #MultipleMyeloma #TongjiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART
Note: Imaging and data have been authorized by the hospital, patients, and patients’ families.


Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
image
9 months ago CAR-T

Putin Says Russia Is Close to Creating Cancer Vaccines. A Look at China’s Advancements

Putin Says Russia Is Close to Creating Cancer Vaccines. A Look at China’s Advancements

Putin

Putin

Recently, a viral piece of information has swept the internet. According to reports, Russian President Putin revealed that Russian scientists are close to developing a cancer vaccine and a new generation of immunomodulatory drugs, which can soon be made available to patients for effective personalized treatment.
 
However, Putin did not specify which type of cancer this vaccine would prevent or how it would prevent it. Nevertheless, this news has spread widely internationally, with some even exaggerating its effectiveness. So, is this really true?
 
It is reported that the information revealed by President Putin is indeed true and will soon be used for personalized treatment. It can be confirmed that this cancer vaccine is a therapeutic vaccine. However, it is not a treatment for all types of cancer but rather a “highly customized” vaccine based on a certain gene sequencing, targeting different mutation sites, including multiple sites, for each patient.
 
Cancer vaccines are a form of active immunotherapy and an important part of tumor immunotherapy. They work by stimulating or restoring the body’s own immune system to prevent cancer development or kill existing tumors. Cancer vaccines mainly include cell vaccines, DNA vaccines, mRNA vaccines, peptide vaccines, dendritic cell vaccines, nano vaccines, etc., and have shown promising clinical efficacy in the treatment of solid tumors such as malignant melanoma, lung cancer, ovarian cancer, and cervical cancer.
Cancer Vaccines

Cancer Vaccines

 
According to data from clinicaltrials.gov, China has about 150 ongoing tumor vaccine projects. China’s first mRNA tumor vaccine is targeting FDA approval, and more tumor mRNA vaccines are emerging, targeting lung cancer, pancreatic cancer, breast cancer, and more.
 

The personalized tumor neoantigen vaccine LK101 injection has been approved for clinical use!

On March 15, 2023, according to the official website of the National Medical Products Administration Drug Evaluation Center (CDE), the new drug clinical trial application (IND) of the personalized tumor neoantigen vaccine “LK101 injection” independently developed by Beijing Likang Life was approved for the treatment of advanced solid tumors.
 
It is reported that this product is the first domestically approved personalized tumor neoantigen vaccine to enter clinical stage and the first completely personalized mRNA editing product approved for clinical stage in China, marking a milestone event in the field of mRNA tumor vaccines in China.
 
On December 22, 2022, LK101 injection submitted a new drug clinical research application (IND) and was accepted. This personalized tumor neoantigen vaccine adopts the form of mRNA-DC (mRNA-dendritic cell) vaccine, which transfects dendritic cells with mRNA encoding tumor neoantigens ex vivo. The vaccine not only has high safety and good tolerance but also can provide patients with long-term anticancer effects.
 

Disease iNeo-Vac-P01 new antigen vaccine!

Personalized cancer vaccines significantly effective against a wide range of advanced solid tumors
The research team of Zhejiang Shao Yifu Hospital designed a peptide-based neoantigen vaccine iNeo-Vac-P01 and conducted a prospective clinical trial, enrolling a total of 22 patients with standard treatment failure and a wide range of advanced solid tumors. Using the iNeo artificial intelligence vaccine design platform, personalized peptide drug preparation and quality control system were used to customize iNeo-Vac-P01 vaccine for each patient.
 
After treatment, the results showed that among the 22 patients with advanced malignant tumors, 20 had no adverse reactions or had mild adverse reactions. The disease control rate was 71.4%, and the median progression-free survival was 4.6 months, with the median survival not yet reached.
 
The study suggests that for patients with advanced solid tumors, iNeo-Vac-P01 monotherapy is feasible and safe. It can induce T-cell-mediated immune responses against tumor neoantigens and may have good anti-tumor efficacy.
 

JCXH-211: Targeting multiple solid tumors with tumor neoantigen mRNA vaccine

Recently, a tumor neoantigen mRNA vaccine developed by Jiachen Xihai Biotechnology Co., Ltd. JCXH-211 has obtained FDA’s IND approval. JCXH-211 is a novel drug based on self-replicating mRNA encoding interleukin-12 (IL-12), which can express IL-12 in the body at a low dose for a long time and is suitable for the potential treatment of various advanced solid tumors.
 
Preclinical studies have shown that JCXH-211 can effectively kill tumor cells, eliminate distant tumors, and prevent tumor recurrence. This excellent tumor clearance effect is due to the strong antiviral immune response induced by RNA replicons and the strong antitumor immune response activated by IL-12. In comprehensive GLP toxicological studies, JCXH-211 has shown high safety.
 
The Phase 1 clinical trial of JCXH-211 will evaluate the efficacy of single-agent JCXH-211 in patients with advanced malignant solid tumors who have progressed or cannot tolerate existing treatments after receiving current treatment. This trial is open to patients aged 18 or older with at least one tumor lesion suitable for IT injection, measurable disease according to RECIST1.1, sufficient organ function, and an ECOG physical status of 0 to 1. Let’s wait and see its effectiveness!
 
#JCXH211 #cancer #CancerVaccine #ImmunotherapyBreakthrough #PersonalizedTreatment #TumorVaccine #mRNAVaccine #NeoantigenVaccine #CancerResearch #PrecisionMedicine #ClinicalTrials #MedicalInnovation

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.